



ASAM The Voice of Addiction Medicine
American Society of Addiction Medicine

Medicaid Coverage of Medications for the Treatment of Opioid Use Disorder

In Pennsylvania between 2008-2012, persons enrolled in

PENNSYLVANIA

substance use treatment programs that prescribed methadone **increased 18.9%**. In 2012 in Pennsylvania, **18.1%** of persons aged 12 and older who met criteria for having a drug use disorder received treatment^a.

State Benefits at a Glance^b...

Methadone

Pennsylvania Medicaid does not cover methadone. In Pennsylvania, methadone for the treatment of opioid use disorder is covered as a medical benefit by behavioral health MCOs under Managed Care (MC) plans.

Buprenorphine/Naloxone film (Suboxone[®]), Buprenorphine/Naloxone tablets (generic), Buprenorphine/Naloxone tablets (Zubsolv^{®c}) and Buprenorphine tablets (generic).

Medication Limitations

Pennsylvania Medicaid covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets under Fee-For-Service (FFS) and MC plans with the following limitations:

- In order to approve Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets for the treatment of opioid use disorder, patients must be enrolled in, or have documented proof of, SUD* counseling.
- Buprenorphine tablets are authorized for use during pregnancy.
- Treatment using Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets is limited to 16mg/day, however, there is no lifetime limit.
- Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets require prior authorization every 3 months.
- Zubsolv appears on Pennsylvania Medicaid's Non-Preferred Drug List.
- In most cases, Zubsolv is subject to the same prior authorization requirements as the surveyed buprenorphine products.

Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets are covered as a pharmacy benefit under FFS and MC plans. Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets are listed on Pennsylvania's preferred drug list for FFS plans. Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets are covered for use in accredited outpatient narcotic treatment programs (NTPs), organized specialty outpatient treatment programs (OTPs) and physician's offices under both FFS and MC plans.



ASAM

The Voice of Addiction Medicine

American Society of Addiction Medicine

State Benefits at a Glance (continued)...

Injectable Naltrexone (VIVITROL®)

Pennsylvania Medicaid covers injectable naltrexone (Vivitrol®) under both FFS and MC plans. Patients **do not** need to be enrolled in, or have documented proof of, SUD* counseling for Vivitrol coverage.

- Vivitrol is covered as a pharmacy benefit under both FFS and MC plans.
- Prior authorization is required for Vivitrol
- Vivitrol appears on Pennsylvania's preferred drug list under FFS plans.

Vivitrol is covered for use in accredited OTPs, NTPs and physician's offices under both FFS and MC plans.

^a Data from SAMHSA's State and Metro Reports accessed http://www.samhsa.gov/data/States_In_Brief_Reports.aspx

^b Data as of spring 2014.


^c Zubsolv was not included in the original survey, as the medication was not FDA approved until fall of 2013. This summary reflects only information related to Preferred Drug List (PDL) and formulary inclusion obtained from pharmacy and State websites.

*In Pennsylvania, substance Use Disorder (SUD) counseling is a covered Medicaid benefit.

Pennsylvania plans to discuss guidelines for opioid use disorder in March, 2014

Medicaid Benefits for Treatment of Opioid Use Disorder Nationwide

Number of Medications Covered under Fee-For-Service Medicaid Plans By State



Data collected by the Avisa Group and Treatment Research Institute 2013-2014